Crossmark

Local immunosuppression in ofatumumab: a series of three cases with bacterial infections near the injection sites

Published Online: 2024-07-29

Published Print: 2024-12

Authors

Bernik, Rok https://orcid.org/0009-0008-1442-3350
Horvat Ledinek, Alenka

Brecl Jakob, Gregor
License Information

Text and Data Mining valid from 2024-07-29

Version of Record valid from 2024-07-29
More Information

Article History

Received: 28 May 2024

Accepted: 22 July 2024

First Online: 29 July 2024

Declarations

:

: The patients gave informed consent to anonymously report cases. Our institution does not require ethical approval for reporting individual cases or case series. The adverse effects reported in this manuscript has been reported to the Agency for Medicinal Products and Medical Devices of the Republic of Slovenia

: Rok Bernik: Education related fees from Roche. Alenka Horvat Ledinek: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Biogen, Lek, Merck, Novartis, Pliva/Teva, Roche, Sanofi Genzyme. Gregor Brecl Jakob: Participated as a clinical investigator and/or received consultation and/or speaker fees from: Amgen, AstraZeneca, Biogen, Lek, Merck, Novartis, Pliva/Teva, Roche, Sanofi Genzyme, Swixx, Viatris.

Document is current